Lynne Kelley M.D.

Lynne Kelley MD, FACS, currently serves as Chief Medical Officer at TISSIUM, a biotechnology company focused on innovative tissue reconstruction solutions, and previously held the role of Vice President Medical Sciences. As the founding CEO and Chief Medical Officer of Xenthera, Kelley leads the development of oncology drugs targeting solid tumors. Additional roles include Interim Chief Medical Officer and consultant at Wedgemere Consulting and Portal Instruments, along with leadership positions at Servier Pharmaceuticals, X4 Pharmaceuticals, Histogenics Corporation, and Senseonics, Incorporated. A seasoned professional in medical affairs, clinical operations, and regulatory submissions, Kelley has extensive experience in oncology, precision medicine, and medical device development, complemented by a medical education from Harvard Medical School and Dartmouth's Geisel School of Medicine.